Recent advances in cystic fibrosis therapeutics have resulted in the use of CFTR modulator pharmacotherapy to improve lung function in patients with cystic fibrosis. How would you rate your understanding of the science and assays for various CFTR class mutations?
Do you apply the 2014 updates in the ECFS Standards of care for Cystic Fibrosis to your management of patients with cystic fibrosis?
How confident are you in the proper use of gene-based Ivacaftor therapeutics for appropriate patients with cystic fibrosis?
Is your practice equipped and prepared to care for adults with cystic fibrosis?
Please take a moment to fill out our reader survey.